BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

TransThera Presents Promising Phase I Results for TT-01488 at 2024 ASH Annual Meeting

TransThera Sciences (Nanjing), Inc. (the "TransThera"), a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on dis...

December 11, 2024 | News

Actinogen Expands Alzheimer’s Trial Across Australia and US, Eyes Interim Results in 2025

Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 Appoints US-based Chief Commercial Officer, Andrew Udell X...

December 10, 2024 | News

Skyhawk Therapeutics Gains Australian Approval to Extend SKY-0515 Huntington’s Disease Trial to 12 Weeks

Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients with Hun...

December 10, 2024 | News

Hansa Biopharma Completes Phase 3 Trial Enrollment Ahead of Schedule for Rare Autoimmune Disease

Hansa Biopharma, "Hansa" announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular ...

December 06, 2024 | News

NTC Announces Positive Phase II Results for NTC014 in Bacterial Conjunctivitis Treatment

NTC, an international R&D focused pharmaceutical company headquartered in Italy, presents positive results from Phase II MIRAKLE study, a mul...

December 06, 2024 | News

Thermo Fisher Enhances Cell Therapy Manufacturing with CTS Detachable Dynabeads™ for CD4+ and CD8+ T Cell Isolation

T cell isolation and controlled release delivers flexibility and control in process development, clinical trials and commercial manufacturing Thermo Fishe...

December 05, 2024 | News

ShiraTronics Launches Pivotal RELIEV-CM2 Trial with First Neuromodulation Implants for Chronic Migraine in the U.S. and Australia

First Implants of Innovative Device Completed in the United States and Australia ShiraTronics, a clinical-stage innovator in neuromodulatio...

December 04, 2024 | News

Everest Medicines Reports Promising Phase 1b/2a Results for EVER001 in Primary Membranous Nephropathy

Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) ...

December 04, 2024 | News

AstraZeneca's Drive to Transform Lung Cancer Care in LMICs

In an exclusive interview with BioPharma APAC, Ti Hwei How, Vice President of International Oncology & Market Access at AstraZeneca, sh...

December 02, 2024 | Interview

Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial

In an exclusive conversation with BioPharma APAC, Stefan Scheidl, VP and Global Head of Ophthalmology Medical Affairs at Roche, delves into the g...

December 02, 2024 | Interview

Shanghai MicuRx Completes Phase III Trial of MRX-4, Advances Toward NDA Submission in China

Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of its Phase III clinical trial of MRX-4 for inject...

December 02, 2024 | News

Minghui Pharmaceutical Announces Positive Phase III Results for MH004 Ointment in Treating Atopic Dermatitis

Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced...

December 02, 2024 | News

Telix and Grand Pharma Dose First Patient in Phase III ZIRCON-CP Trial for ccRCC Imaging in China

Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and Grand Pharmaceutical Group Limited (00512.HK, Grand Pharma) announce th...

November 29, 2024 | News

Allink Biotherapeutics Secures $42 Million Series A Funding to Drive Global Expansion of Next-Gen ADC and Bispecific Antibody Therapies

Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutic...

November 29, 2024 | News

Stay Connected